Abstract

We previously reported that shokyo and kankyo, which are water-extracted fractions of ginger, reduced LPS-induced PGE2 production in human gingival fibroblasts. In this study, we examined the effects of these herbs on LPS-treated mouse macrophage RAW264.7 cells. Both shokyo and kankyo reduced LPS-induced PGE2 production in a concentration-dependent manner. Shokyo and kankyo did not inhibit cyclooxygenase (COX) activity, nor did they alter the expression of molecules in the arachidonic acid cascade. In addition, these herbs did not alter NF-κB p65 translocation into nucleus, or phosphorylation of p65 or ERK. These results suggest that shokyo and kankyo inhibit cPLA2 activity. Although 6-shogaol produced similar results to those of shokyo and kankyo, the concentration of 6-shogaol required for the reduction of PGE2 production were higher than those of 6-shogaol in shokyo and kankyo. Therefore, several gingerols and shogaols other than 6-shogaol may play a role in the reduction of LPS-induced PGE2 production. Thus, 6-shogaol, and other gingerols and shogaols inhibit cPLA2 activity and reduce LPS-induced PGE2 production via a different mechanism from traditional anti-inflammatory drugs. Moreover, kampo medicines that contain shokyo or kankyo are considered to be effective for inflammatory diseases.

Highlights

  • Japanese traditional medicines are used for the treatment of several inflammatory diseases

  • We focused on the inflammatory effects of these kampo medicines, and found that lipopolysaccharide (LPS)-induced prostaglandin E2 (PGE2) production by human gingival fibroblasts (HGFs) were reduced by several kampo medicines, including shosaikoto (TJ9) (Ara et al, 2008), orento (TJ-120) (Ara et al, 2010), hangeshashinto (TJ-14) (Nakazono et al, 2010), kakkonto (TJ-1) (Kitamura, Urano & Ara, 2014), shinbuto (TJ-30), and ninjinto (TJ-32) (Ara & Sogawa, 2017)

  • We first examined the effects of shokyo and kankyo on RAW264.7 cell viability

Read more

Summary

Introduction

Japanese traditional medicines (kampo medicines) are used for the treatment of several inflammatory diseases. We focused on the inflammatory effects of these kampo medicines, and found that lipopolysaccharide (LPS)-induced PGE2 production by human gingival fibroblasts (HGFs) were reduced by several kampo medicines, including shosaikoto (TJ9) (Ara et al, 2008), orento (TJ-120) (Ara et al, 2010), hangeshashinto (TJ-14) (Nakazono et al, 2010), kakkonto (TJ-1) (Kitamura, Urano & Ara, 2014), shinbuto (TJ-30), and ninjinto (TJ-32) (Ara & Sogawa, 2017). Effects of shokyo (Zingiberis Rhizoma) and kankyo (Zingiberis Processum Rhizoma) on prostaglandin E2 production in lipopolysaccharide-treated mouse macrophage RAW264.7 cells. Shokyo and kankyo strongly reduced LPS-induced PGE2 production These results suggested that kampo medicines that include shokyo or kankyo have anti-inflammatory effects for periodontal disease

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call